SEP 7, 2026 · JOURNAL ARTICLE
An exploratory case series of sequential stereotactic body radiotherapy and tislelizumab after platinum-doublet chemotherapy in stage IIIB/C–IV non-squamous NSCLC
Frontiers in Immunology
Single-center exploratory pilot case series with deliberate selection bias, small sample, and descriptive endpoints only; generates hypothesis-building observations insufficient for definitive therapeutic conclusions.
Reported
Sample size8
1-year PFS rate25%
Median PFS10.14 months